De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.
Google Scholar
Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42:354–73.
Google Scholar
Chan Y-T, Wu J, Lu Y, Li Q, Feng Z, Xu L, et al. Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC. Mol Cancer. 2024;23:74.
Google Scholar
Xu J, Fang S, Dong X, Liang C, Yang R, Zhao Y, et al. Hypoxia-induced upregulation of HIF1A-AS3 promotes MSC transition to cancer-associated fibroblasts and confers drug resistance in gastric cancer. Drug Resistance Updates. 2025;82:101275.
Google Scholar
Chen K-L, Huang S-W, Yao J-J, He S-W, Gong S, Tan X-R, et al. LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein. Drug Resistance Updates. 2024;76:101111.
Google Scholar
Wen Q, Huang M, Xie J, Liu R, Miao Q, Huang J, et al. lncRNA SYTL5-OT4 promotes vessel co-option by inhibiting the autophagic degradation of ASCT2. Drug Resistance Updates. 2023;69:100975.
Google Scholar
Ferrer J, Dimitrova N. Transcription regulation by long non-coding RNAs: mechanisms and disease relevance. Nat Rev Mol Cell Biol. 2024;25:396–415.
Google Scholar
Bester AC, Lee JD, Chavez A, Lee Y-R, Nachmani D, Vora S, et al. An integrated genome-wide CRISPRa approach to functionalize lncRNAs in drug resistance. Cell. 2018;173:649–64.e20.
Google Scholar
Fei T, Chen Y, Xiao T, Li W, Cato L, Zhang P, et al. Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. Proc Natl Acad Sci USA 2017;114. https://doi.org/10.1073/pnas.1617467114.
Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, et al. CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nat Commun. 2023;14:252.
Google Scholar
Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, et al. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens. Nature. 2019;568:511–6.
Google Scholar
Shi J, Wang E, Milazzo JP, Wang Z, Kinney JB, Vakoc CR. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol. 2015;33:661–7.
Google Scholar
Han K, Jeng EE, Hess GT, Morgens DW, Li A, Bassik MC. Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nat Biotechnol. 2017;35:463–74.
Google Scholar
Bennardo N, Cheng A, Huang N, Stark JM. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet. 2008;4:e1000110.
Google Scholar
Nakanishi K, Cavallo F, Brunet E, Jasin M. Homologous recombination assay for interstrand cross-link repair. In: Tsubouchi H, edior. DNA Recombination. Totowa, NJ: Humana Press; 2011. p. 283–91.
Li L, An X-N, Ruan Y-T, Liang X, Hao J-L, Gao G-X, et al. LncRNA AC021683.2 promotes chemotherapy resistance in acute myeloid leukemia. Iscience. 2025;28:113439.
Google Scholar
Liu Y, Cao Z, Wang Y, Guo Y, Xu P, Yuan P, et al. Genome-wide screening for functional long noncoding RNAs in human cells by Cas9 targeting of splice sites. Nat Biotechnol. 2018;36:1203–10.
Google Scholar
Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, et al. A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell Reports. 2016;17:1193–205.
Google Scholar
Luk ISU, Shrestha R, Xue H, Wang Y, Zhang F, Lin D, et al. BIRC6 targeting as potential therapy for advanced, enzalutamide-resistant prostate cancer. Clin Cancer Res. 2017;23:1542–51.
Google Scholar
Li D, Shen L, Zhang X, Chen Z, Huang P, Huang C, et al. LncRNA ELF3-AS1 inhibits gastric cancer by forming a negative feedback loop with SNAI2 and regulates ELF3 mRNA stability via interacting with ILF2/ILF3 complex. J Exp Clin Cancer Res. 2022;41:332.
Google Scholar
Zhang X, Bustos MA, Gross R, Ramos RI, Takeshima T, Mills GB, et al. Interleukin enhancer-binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma. Clin Transl Med. 2021;11:e608.
Google Scholar
Yang C, Zang W, Tang Z, Ji Y, Xu R, Yang Y, et al. A20/TNFAIP3 Regulates the DNA damage response and mediates tumor cell resistance to DNA-damaging therapy. Cancer Res. 2018;78:1069–82.
Google Scholar
Vasaitis TS, Bruno RD, Njar VCO. CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol. 2011;125:23–31.
Google Scholar
Zhu H, Garcia JA. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor. Curr Oncol Rep. 2013;15:105–12.
Google Scholar
Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, et al. Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide. Eur Urol. 2018;74:218–25.
Google Scholar
Francini E, Agarwal N, Castro E, Cheng HH, Chi KN, Clarke N, et al. Intensification approaches and treatment sequencing in metastatic castration-resistant prostate cancer: a systematic review. Eur Urol. 2025;87:29–46.
Google Scholar
Hussain M, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller CJ, et al. Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). Clin Cancer Res. 2024;30:4318–28.
Google Scholar
Xie J, Guo H, Dong B, Chen W, Jin C, Xu Q, et al. Olaparib combined with abiraterone versus olaparib monotherapy for patients with metastatic castration-resistant prostate cancer progressing after abiraterone and harboring DNA damage repair deficiency: a multicenter real-world study. Eur Urol Oncol. 2024;7:1088–96.
Google Scholar
Wyatt AW, Azad AA, Volik SV, Annala M, Beja K, McConeghy B, et al. Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncol. 2016;2:1598.
Google Scholar
Sardar S, McNair CM, Ravindranath L, Chand SN, Yuan W, Bogdan D, et al. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer. Oncogene. 2024;43:3197–213.
Google Scholar
Yang X, Zhang S, He C, Xue P, Zhang L, He Z, et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Mol Cancer. 2020;19:46.
Google Scholar
Hua Q, Jin M, Mi B, Xu F, Li T, Zhao L, et al. LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis. J Hematol Oncol. 2019;12:91.
Google Scholar
Xin Z, Hu C, Zhang C, Liu M, Li J, Sun X, et al. LncRNA-HMG incites colorectal cancer cells to chemoresistance via repressing p53-mediated ferroptosis. Redox Biol. 2024;77:103362.
Google Scholar
Zhao Q, Li B, Zhang X, Zhao H, Xue W, Yuan Z, et al. M2 macrophage-derived lncRNA NORAD in EVs promotes NSCLC progression via miR-520g-3p/SMIM22/GALE axis. npj Precis Onc. 2024;8:185.
Google Scholar
Zheng Z, Wu M, Li H, Xu W, Yang M, Pan K, et al. Downregulation of AC092894.1 promotes oxaliplatin resistance in colorectal cancer via the USP3/AR/RASGRP3 axis. BMC Med. 2023;21:132.
Google Scholar
Chuang T-W, Su C-H, Wu P-Y, Chang Y-M, Tarn W-Y. LncRNA HOTAIRM1 functions in DNA double-strand break repair via its association with DNA repair and mRNA surveillance factors. Nucleic Acids Res. 2023;51:3166–84.
Google Scholar
Eptaminitaki GC, Stellas D, Bonavida B, Baritaki S. Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability. Drug Resistance Updates. 2022;65:100866.
Google Scholar
Luo J, Wang K, Yeh S, Sun Y, Liang L, Xiao Y, et al. LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling. Nat Commun. 2019;10:2571.
Google Scholar
Tamura A, Yamagata K, Kono T, Fujimoto M, Fuchigami T, Nishimura M, et al. p53-inducible lncRNA LOC644656 causes genotoxic stress-induced stem cell maldifferentiation and cancer chemoresistance. Nat Commun. 2025;16:4818.
Google Scholar
Michelini F, Pitchiaya S, Vitelli V, Sharma S, Gioia U, Pessina F, et al. Damage-induced lncRNAs control the DNA damage response through interaction with DDRNAs at individual double-strand breaks. Nat Cell Biol. 2017;19:1400–11.
Google Scholar
Kaimala S, Lootah SS, Mehra N, Kumar CA, Marzooqi SA, Sampath P, et al. The long non-coding RNA obesity-related (Obr) contributes to lipid metabolism through epigenetic regulation. Adv Sci. 2024;11:2401939.
Google Scholar
Oo JA, Warwick T, Pálfi K, Lam F, McNicoll F, Prieto-Garcia C, et al. Long non-coding RNAs direct the SWI/SNF complex to cell type-specific enhancers. Nat Commun. 2025;16:131.
Google Scholar
Mathy NW, Chen X-M. Long non-coding RNAs (lncRNAs) and their transcriptional control of inflammatory responses. J Biol Chem. 2017;292:12375–82.
Google Scholar
Zhang H, Zhang N, Liu Y, Su P, Liang Y, Li Y, et al. Epigenetic regulation of NAMPT by NAMPT-AS drives metastatic progression in triple-negative breast cancer. Cancer Res. 2019;79:3347–59.
Google Scholar
Zhang A, Zhao JC, Kim J, Fong K, Yang YA, Chakravarti D, et al. LncRNA HOTAIR enhances the androgen-receptor-mediated transcriptional program and drives castration-resistant prostate cancer. Cell Rep. 2015;13:209–21.
Google Scholar
Zhang B, Zhang M, Shen C, Liu G, Zhang F, Hou J, et al. LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance. Cell Death Dis. 2021;12:856.
Google Scholar
Li X, Wang X, Song W, Xu H, Huang R, Wang Y, et al. Oncogenic Properties of NEAT1 in prostate cancer cells depend on the CDC5L–AGRN transcriptional regulation circuit. Cancer Res. 2018;78:4138–49.
Google Scholar
Liu S-S, Jiang T-X, Bu F, Zhao J-L, Wang G-F, Yang G-H, et al. Molecular mechanisms underlying the BIRC6-mediated regulation of apoptosis and autophagy. Nat Commun. 2024;15:891.
Google Scholar
Dietz L, Ellison CJ, Riechmann C, Cassidy CK, Felfoldi FD, Pinto-Fernández A, et al. Structural basis for SMAC-mediated antagonism of caspase inhibition by the giant ubiquitin ligase BIRC6. Science. 2023;379:1112–7.
Google Scholar
Hunkeler M, Jin CY, Fischer ES. Structures of BIRC6-client complexes provide a mechanism of SMAC-mediated release of caspases. Science. 2023;379:1105–11.
Google Scholar
Ehrmann JF, Grabarczyk DB, Heinke M, Deszcz L, Kurzbauer R, Hudecz O, et al. Structural basis for regulation of apoptosis and autophagy by the BIRC6/SMAC complex. Science. 2023;379:1117–23.
Google Scholar
Gómez Bergna SM, Marchesini A, Amorós Morales LC, Arrías PN, Farina HG, Romanowski V, et al. Exploring the role of the inhibitor of apoptosis BIRC6 in breast cancer: a database analysis. JCO Clinical Cancer Informatics. 2022;e2200093.
Li Y, Tan Y, Wen L, Xing Z, Wang C, Zhang L, et al. Overexpression of BIRC6 driven by EGF-JNK-HECTD1 signaling is a potential therapeutic target for triple-negative breast cancer. Mol Therapy Nucleic Acids. 2021;26:798–812.
Google Scholar
Hu T, Weng S, Tang W, Xue R, Chen S, Cai G, et al. Overexpression of BIRC6 Is a predictor of prognosis for colorectal cancer. PLoS ONE. 2015;10:e0125281.
Google Scholar
Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22:298–305.
Google Scholar
Ding Z, Xu C, Sahu I, Wang Y, Fu Z, Huang M, et al. Structural snapshots of 26S proteasome reveal tetraubiquitin-induced conformations. Mol Cell. 2019;73:1150–61.e6.
Google Scholar
Kiss L, James LC, Schulman BA. UbiREAD deciphers proteasomal degradation code of homotypic and branched K48 and K63 ubiquitin chains. Mol Cell. 2025;85:1467–76.e6.
Google Scholar
Liu P, Gan W, Su S, Hauenstein AV, Fu T, Brasher B, et al. K63-linked polyubiquitin chains bind to DNA to facilitate DNA damage repair. Sci Signal. 2018;11:eaar8133.
Google Scholar
Xia L, Xing Y, Ye X, Wu Y, Yang Y, Yin Z, et al. TRIM21-driven K63-linked ubiquitination of RBM38c, as a novel interactor of BECN1, contributes to DNA damage-induced autophagy. Cell Death Differ. 2025;32:1317–35.
Google Scholar
Zhu B, Yan K, Li L, Lin M, Zhang S, He Q, et al. K63-linked ubiquitination of FANCG is required for its association with the Rap80-BRCA1 complex to modulate homologous recombination repair of DNA interstand crosslinks. Oncogene. 2015;34:2867–78.
Google Scholar
Vereecke L, Beyaert R, Van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009;30:383–91.
Google Scholar
Luo C, Zhang R, Guo R, Wu L, Xue T, He Y, et al. Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells. Immunity. 2025;58:745–65.e9.
Google Scholar
Luo M, Wang X, Wu S, Yang C, Su Q, Huang L, et al. A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block “eat-me” signal. Sig Transduct Target Ther. 2023;8:312.
Google Scholar
Han M-T, Pei H, Sun Q-Q, Wang C-L, Li P, Xie Y-Y, et al. ZY-444 inhibits the growth and metastasis of prostate cancer by targeting TNFAIP3 through TNF signaling pathway. Am J Cancer Res. 2023;13:1533–46.
Google Scholar
Perez-Riverol Y, Bandla C, Kundu DJ, Kamatchinathan S, Bai J, Hewapathirana S, et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res. 2025;53:D543–53.
Google Scholar
Ma J, Chen T, Wu S, Yang C, Bai M, Shu K, et al. iProX: an integrated proteome resource. Nucleic Acids Res. 2019;47:D1211–7.
Google Scholar
Deutsch EW, Bandeira N, Sharma V, Perez-Riverol Y, Carver JJ, Kundu DJ, et al. The ProteomeXchange consortium in 2020: Enabling ‘big data’ approaches in proteomics. Nucleic Acids Res. 2020;48:D1145–52.
Google Scholar
